Innate immune mechanisms can control disease progression in HIV-positive patients

February 24, 2010

HIV/AIDS remains one of the world's most significant public health challenges, particularly in developing countries. The Human Immunodeficiency Virus (HIV-1), the variant responsible for the pandemic, has the ability to infect different cell types such as T cells, macrophages and dendritic cells (DC). These latter cells are crucial in the defense against infectious agents and play a major role in viral pathogenesis. The present study, led by researchers from Hospital Clinic de Barcelona-IDIBAPS, within the framework of HIVACAT, shows for the first time that dendritic cells in HIV-infected patients who spontaneously control the infection produce high levels of α-defensins 1 -3. This is associated with slower disease progression, suggesting potential diagnostic, therapeutic and preventive implications. The first author of this study is Dr. Marta Rodriguez-Garcia, Emili Letang Fellowship award from Hospital Clinic of Barcelona for her work in this line of research, and currently a postdoc at The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard. The senior researchers of the study are Dr. Teresa Gallart, from the Immunology Service of Hospital Clinic and collaborator of the IDIBAPS team on Infectious Diseases and AIDS, and Dr. Josep M ª Gatell, Head of the Infectious Diseases Department at the Hospital Clinic and leader of the same IDIBAPS team.

The study was done in collaboration with the Catalan Center for HIV Vaccine Research and Development (HIVACAT), a public-private partnership involving IrsiCaixa Foundation and the Infectious Diseases Department at the Hospital Clinic of Barcelona. The research conducted within this initiative is made in coordination with Esteve and with the support of "La Caixa" Foundation and the Health and the Innovation, Universities and Enterprise Departments of the Generalitat de Catalunya.

Defensins are endogenous antimicrobial peptides with broad-spectrum antimicrobial properties and immunomodulatory effects. They have a potent anti-HIV activity, acting directly on the virus and also in target cells. According to its structure, human defensins are classified into two subfamilies: α-defensins and β-defensins, both with anti-HIV activity. The α-defensins, also known as human neutrophil peptides, are stored in neutrophils and, to a lesser extent, in other types of leukocytes. Although the anti-HIV activity of α-defensins1-3 has been clearly demonstrated in vitro, their possible protective role during HIV infection in vivo remains uncertain.

The authors recently demonstrated that α-defensins1-3 are produced by monocyte-derived immature dendritic cells (MDDC) in healthy individuals and they are able to modulate the maduration and differentiation process of MDDC. Dendritic cells (DC) are the main antigen-presenting cells and play a key role in the innate immune response against different viral infections, especially during the response generated against HIV. Due to their mucosal localization, DC are thought to be one of the first cells that encounter the HIV and, after migration to the lymph nodes, they would mediate the transmission of HIV-1 virions to CD4 T cells, the main source of HIV-1 replication and dissemination. For this study, a valid model of in vivo myeloid DC, the MDDC, was analysed. These might be one of the key cells involved in early HIV infection, and therefore their capacity to produce and release α-defensins1-3 by DC may have physiological relevance.

The study enrolled healthy, non-infected controls and HIV-1-infected subjects. These HIV-1-infected individuals were classified as: elite controllers (patients able to spontaneously control VIH infection in the absence of therapy, with plasma viral loads below 50 RNA copies/ml and that constitute the 5% of the infected population), viremic controllers (with PVLs higher than 50 and lower than 5000 RNA copies/ml without therapy), viremic non-controllers (with PVLs higher than 5000 RNA copies/ml without therapy) and patients with antiretroviral therapy (HAART). All patients had CD4 T cell counts higher than 450 cell/mm3. Results revealed that immature dendritic cells from HIV-infected patients who control the infection produced higher levels of α-defensins1-3 than the non-infected control group and these levels were associated with a better control of HIV infection and slower disease progression. The study of controller patients, especially elite controllers, is of particular relevance since these individuals demonstrate that natural control of HIV replication in the absence of antiretroviral therapy is possible.

The findings of this study show that of α-defensins1-3 may be potential prophylactic agents and open a new line of investigation to treat HIV / AIDS, although further studies will be needed to determine the possible value of these molecules as an important diagnostic and therapeutic tool to arrest or slow the replication of HIV in infected patients.
-end-


IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.